All American Pharmaceutical Gains FDA Orphan Drug Status for Juvenile Rheumatoid Arthritis

April 11, 2013

The company says the benefit of its compound is its lack of side effects.

FDA has granted dietary supplement manufacturer All American Pharmaceutical & Natural Foods Corp. (AAP; Billings, MT) orphan drug status for one of its patent-pending compounds, in the area of Juvenile Rheumatoid Arthritis (JRA). JRA affects children under the age of 16 and causes joint pain, swelling, and stiffness.

Orphan drug status clears the way for AAP to begin a second clinical study in the JRA population. The company says the benefit of its compound is its lack of side effects. “In this next phase of the research, which will follow FDA guidelines and be conducted in conjunction with a U.S. university, we’ll continue to explore the role of the new drug on joint and related tissue inflammation,” says Jeff Golini, AAP’s executive scientist.

Related Content:

Joint & Bone Health